|
Cutting Image Histology
Cutting Image Histology (CIH) LLC provides high quality histology, immunohistochemistry, and histopatholology services to the pharmaceutical, biotechnology, and academic research communities. Located in Ann Arbor Michigan, CIH is privately owned and operated by Wendy Rosebury-Smith and Theresa Cody. With more than 50 years of combined diverse experiences in both drug discovery and safety assessment (GLP) environments, CIH is committed to meeting the specialized needs of today’s researchers in the most efficient and cost-effective manner. CIH has extensive experience with preclinical models of cardiovascular diseases including animal model development and validation, experimental designs, and histologic endpoints. Wendy and Theresa have formed a strategic partnership with Dr. Robert Sigler, a veterinarian pathologist (DVM, Dipl. ACVP) with more than 20 years of experience with toxicological studies of small and macromolecules in development as well as preclinical discovery. Please see our individual bio’s to learn more about us.
Wendy Rosebury-Smith, A.A.S., HT (ASCP) President and Co-Founder, Cutting Image Histology |
||||||
|
Wendy has 25
years of experience in the field of histotechnology with 21 years
specifically in the pharmaceutical industry. Prior to co-founding Cutting
Image Histology in
Theresa Cody, A.S., HT (ASCP), QIHC Vice-President and Co-Founder, Cutting Image Histology
Theresa’s professional histological expertise spans twenty-seven years.
She has worked twenty-one years as a research scientist in the
pharmaceutical industry and her specialty’s helped to support Pathology
and Experimental Toxicology, Drug Safety and
Dr. Robert Sigler, DVM, Ph.D., Dipl. ACVP Veterinary Pathologist and IND Services Dr. Robert Sigler, Founder, Vet Pathology and IND Services, has 22 years experience as a drug development pathologist and study director at Parke-Davis, Pfizer and Esperion Therapeutics. After receiving his DVM from Michigan State University he obtained ACVP board-certification after finishing his residency at University of Tennessee College of Vet Medicine and his Ph.D. in Pathology from the University of Maryland Medical School. He has experience in large pharma as well as start-ups and small companies, serving as pathologist and study director in numberous GLP safety studies and investigational, discovery and development projects for drug candidates. He has co-authored several IND applications as well as safety assessments and FDA briefing documents. He performed extensive work supporting the safety package for Lipitor and Neurontin, marketed by Parke-Davis and Pfizer. He was Director of Pathology (Esperion Therapeutics, Inc, a company acquired by Pfizer. He was former Head of Pathology and Toxicology for Avidimer Therapeutics Inc. developing nanoparticles for targeted cancer and rheumatoid arthritis therapy. Dr. Sigler is currently a consulting pathologist, collaborating with cancer investigators at Van Andel Research Institute and Jobst Vascular Laboratory at the University of Michigan, working on animal models of thrombosis and endothelial injury. He is a consulting pathologist for WuXi Apptec and CanBioPharma is teamed with Cutting Image Histology to provide extensive histopathology and consulting services for research investigators and companies engaged in drug discovery and development. | ||||||
| ||||||
